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Advances in genomics have revealed many of the genetic underpinnings of human disease,
but exposomics methods are currently inadequate to obtain a similar level of understanding
of environmental contributions to human disease. Exposomics methods are limited by low
abundance of xenobiotic metabolites and lack of authentic standards, which precludes
identiﬁcation using solely mass spectrometry-based criteria. Here, we develop and validate a
method for enzymatic generation of xenobiotic metabolites for use with high-resolution mass
spectrometry (HRMS) for chemical identiﬁcation. Generated xenobiotic metabolites were
used to conﬁrm identities of respective metabolites in mice and human samples based upon
accurate mass, retention time and co-occurrence with related xenobiotic metabolites. The
results establish a generally applicable enzyme-based identiﬁcation (EBI) for mass spectrometry identiﬁcation of xenobiotic metabolites and could complement existing criteria for
chemical identiﬁcation.
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H

umans are exposed to tens of thousands of xenobiotic
chemicals from the diet, drugs, environmental and
occupational exposures, commercial products, and the
microbiome1. Together with endogenously generated metabolites
of the human metabolome, these are predicted to include over
one million distinct chemical entities, representing a substantial
analytical challenge for human exposome research2,3. To overcome the limitation in the number of chemicals measured with
targeted methods, high-resolution mass spectrometry (HRMS)
uses liquid chromatography with ultra-high resolution mass
spectrometry and computational methods to measure chemicals
as mass spectral signals without a priori knowledge of chemical
identity3. This ﬁlls an important need to deliver -omics scale
chemical data for environmental epidemiology to detect unrecognized health hazards4 but increases the need for additional
approaches for chemical identiﬁcation.
Xenobiotics are typically 3 to 5 orders of magnitude lower in
abundance than endogenous metabolites and may be present in
only a small fraction of human samples5. Conﬁdent identiﬁcation of
low-abundance xenobiotics is limited because mass spectrometrybased criteria require authentic standards and mass fragmentation
spectra (MS2 or MSn)6,7. Standards are not available for most
xenobiotic metabolites and only the top 1000–2000 highest intensity
features have useful MS2 or MSn spectra. Therefore, additional
procedures are needed to complement accurate mass mass-tocharge ratios (m/z) for chemical identiﬁcation.
Human enzymes convert xenobiotics to phase I and II metabolites.
Usually, these related xenobiotic metabolites are expected to be
present in samples with real exposures. With HRMS, computational
approaches provide a strategy to test for co-detection of related
xenobiotic metabolites by use of biological precursor–product relationships and metabolite–metabolite correlations. For example,
multiple metabolites of naphthalene and another polycyclic aromatic
hydrocarbon (PAH) were correlated and detected in military personnel exposed to burn pits8, providing credibility for PAH exposure
despite signal intensities too low for MS2 analysis. Similarly, a
metabolome-wide association study of the dichlorodiphenyltrichloroethane (DDT) metabolite chlorophenyl acetic acid identiﬁed
two other correlated DDT metabolites9. While in silico tools for the
prediction of xenobiotic metabolites10 and associated fragmentation
spectra11–13 are available, the lack of readily available authentic
standards for most xenobiotic biotransformation products limits our
ability to identify xenobiotic metabolites in real samples.
In the present study, we develop a system to generate xenobiotic metabolites in a high-throughput manner to enhance mass
spectrometry capabilities to identify xenobiotic metabolites in
human samples. We use biological preparations with xenobiotic
biotransformation enzyme activities (pooled human liver S9
fractions) to generate metabolites from a panel of xenobiotics,
including some with known biotransformation products. We
characterize metabolic products by accurate mass m/z, retention
time, MSn, and stable isotope methods and match these to
xenobiotic metabolites detected in mouse and human circulation.
Our data show that related xenobiotic metabolites co-occur in
human samples with documented exposures, and we apply this
principle to identify undocumented environmental exposures.
The results establish a method to provide authentic xenobiotic
metabolites and associated stable isotopic forms for use with
HRMS to improve conﬁdence in the identiﬁcation of low abundance xenobiotic metabolites in humans.
Results
Workﬂow for enzymatic generation of xenobiotic metabolites.
We aimed to develop a platform that enabled high-throughput
enzymatic production of phase I and phase II xenobiotic
2

metabolites. We used pooled human liver S9 fractions based upon
previous ﬁndings that they are more representative of hepatocyte
metabolism compared to microsomes and are more amenable for
high-throughput
screening
applications
compared
to
hepatocytes14. S9 fractions contain both microsomal and cytosolic subcellular fractions and include most phase I (cytochrome
P450s, ﬂavin monooxygenases, and aldehyde oxidases) and phase
II (sulfotransferases, methyltransferases, glutathione S-transferases, N-acetyl transferases, and UDP-glucuronosyltransferases)
biotransformation enzymes15–21. We prepared human liver S9
fractions with required cofactors in a 96-well plate format
(Fig. 1a) which enabled the production of phase I and phase II
metabolites (Fig. 1b) from multiple xenobiotics in a single plate.
Reaction extracts were analyzed with HRMS to build retention
time and spectral libraries for use with HRMS analyses of human
samples (Fig. 1c).
Production of phase I and II metabolites by human S9
enzymes. To test whether standard conditions for S9 incubations
could be used to produce biotransformation products of diverse
xenobiotics, we tested 139 xenobiotics from environmental,
pharmaceutical, and dietary/personal care products. Phase I and
II metabolites for many (but not all) of these xenobiotics have
been previously documented. Our data show that expected phase
I and phase II metabolites were not detected at time 0 and
increased with incubation time. For example, MS1 peak areas for
hydroxy beta-naphthoﬂavone, beta-naphthoﬂavone dihydrodiol,
hydroxy beta-naphthoﬂavone glucuronide, and hydroxy betanaphthoﬂavone sulfate (Fig. 2a–d) increased with time and were
not detected in the 0 h sample. Overall, more than 90% of
expected metabolites from selected metabolites with wellcharacterized metabolism were detected in incubation extracts
after 24 h (Fig. 2e). It is important to note that not all metabolites
were detected at sufﬁcient levels to collect mass fragmentation
spectra. Extracted ion chromatograms and summarized data
(MS1 m/z, adduct form, retention time, analytic method, MS2 if
available) for other xenobiotic precursors are available online
(http://metabolomics.cloud/#/project/CIDC001) and in supplementary data (Supplementary Fig. 1, Supplementary data 1). Raw
ﬁles are available on Metabolomics Workbench (DOI: 10.21228/
M8N97J). Thus, the present results show that the use of standardized human liver S9 fraction incubations is suitable as a
platform for the production of expected phase I and phase II
metabolites of diverse xenobiotics.
Compound ID aided by isotope labels and prior knowledge. To
further characterize S9-enzyme generated metabolites, we used
isotopically labeled xenobiotic precursors to aid structure elucidation. Bupropion is mainly metabolized by CYP2B6, which
performs a stereospeciﬁc hydroxylation to form (2S,3S)hydroxybupropion22. However, 4′-hydroxybupropion, which
shares the same exact mass, is also an expected minor product.
Using d9-bupropion with S9 enzymes, we can differentiate
between the formation of (2S,3S)-hydroxybupropion (Fig. 3a) and
4′-hydroxybupropion (Fig. 3b). (2S,3S)-hydroxybupropion is a
heterocycle which loses one deuterium; whereas, 4′-hydroxybupropion is formed without loss of the deuterium label. Our
data show the major product is d8-(2S,3S)-hydroxybupropion
(264.1600 m/z) (Fig. 3c), with peak intensities, 10× higher than
d9-4′-hydroxybupropion (265.1666 m/z) after 24 h (Fig. 3d).
Using unlabeled bupropion, 256.1099 m/z alone does not discriminate between (2S,3S)-hydroxybupropion and 4′-hydroxybupropion (Fig. 3e). MS2 spectra collected from 256.1099 m/z
are consistent with (2S,3S)-hydroxybupropion since we observe a
fragment 184.0518 m/z (C9H11ClNO+) as opposed to an
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Fig. 1 Enzymatic generation of xenobiotic metabolites for mass spectrometry-based chemical identiﬁcation. a Human liver S9 enzyme prepared in a 96well plate format capable of performing multiple xenobiotic reactions in a single plate. Human liver S9 enzymes perform Phase I and II biotransformation
reactions to generate xenobiotic metabolites or other downstream adducts from reactive intermediates. b High-resolution mass spectrometry (HRMS)
analysis of enzyme-generated xenobiotic metabolites provides authentic metabolites for matching accurate mass m/z, retention time (RT), and MS2 (if
available) to detected metabolites in humans. Colored dots in each m/z RT dot plot represent spectral features that are identiﬁed from in vitro S9 reactions
that could be matched to features detected in clinical or experimental studies. Co-occurrence of related xenobiotics in samples increases conﬁdence in the
identiﬁcation of suspected exposure.
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Fig. 2 Human liver S9 enzymes generate Phase I and II xenobiotic metabolites in a time-dependent manner. Using standard conditions for S9 reactions,
expected Phase I (a, b) and II (c, d) metabolites are formed in a time-dependent manner. Each plot depicts the extracted ion chromatograms of predicted
metabolites of beta-naphthoﬂavone at 0, 2, 6, and 24 h. Metabolites were identiﬁed if they produced a time-dependent increase in MS1 signal
corresponding to the accurate mass of a predicted or expected metabolite. e Formation of expected metabolites in a time-dependent manner for wellcharacterized xenobiotics using S9 enzymes.

expected 200.0473 m/z (C9H11ClNO2+) if the oxidation occurred
on the aromatic ring (Fig. 3f).
Identiﬁcation of unreported metabolites with stable isotopes.
Full scan data collection for HRMS enables untargeted analysis to

identify potential unreported metabolites. Here, we tested whether other spectral features that increased with time of S9 enzyme
incubation could be unreported xenobiotic metabolites. To distinguish nonspeciﬁc reaction products from reaction products of
test compound(s), we implemented an additional ﬁlter to account
for mass differences due to labeling. For example, in the unlabeled

NATURE COMMUNICATIONS | (2021)12:5418 | https://doi.org/10.1038/s41467-021-25698-x | www.nature.com/naturecommunications

3

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25698-x

a

c

d8d
-(2S,3S)-hydroxybupropion
8-2,3 hydroxybupropion

e

Hydroxybupropion
256.1099 m/z

2

1
0.5

Expected: 264.1600 m/z

1.25

0.5
1.25

RT (min)

24h
0h

6
4
2

264.1600 m/z

f

Intensity
(x 105)

Peak Intensity
(x 106)

24h
0h

1

0
0.00

8

RT (min)

d9-4’-hydroxybupropion
-4-hydroxybupropion
265.1674 m/z
2
1.5

10

0
D8-2,3-hydroxybupropion
0.00
1.25
2.50

2.50

RT (min)

d

Expected: 265.1674 m/z

24h
0h

1.5

0
0.00

b

Peak Intensity
(x 106)

Peak Intensity
(x 106)

264.1600 m/z

2.50

184.0518
256.1093

m/z

Fig. 3 Stable-isotope assisted metabolite identiﬁcation. Use of d9-bupropion with S9 enzyme system produces either a d8-(2S,3S)-hydroxybupropion or b
d9-4′-hydroxybupropion. c Extracted ion chromatogram of 264.1600 m/z (d8-(2S,3S)-hydroxybupropion) at 0 and 24 h with the addition of d9-bupropion.
d Extraction ion chromatogram of 265.1674 m/z (d9-4′ hydroxybupropion) at 0 and 24 h with addition of d9 bupropion. e Extracted ion chromatogram of
256.1099 m/z (hydroxybupropion) at 0 and 24 h with addition of bupropion. f Mass fragmentation spectrum (MS2) of 256.1099 m/z (black) is consistent
with (2S,3S)-hydroxybupropion.

caffeine reaction, 485 features were positively associated (R > 0.9)
with time. Of these 485 features, we were able to identify two
metabolites that were similarly increased with the addition of
isotopically labeled (13C3 or D3) caffeine. Paraxanthine is the
expected major product of caffeine metabolism and we observed
increases in both unlabeled (181.0720 m/z 31 s RT) and labeled
(13C2—183.0786 m/z 31 s RT, D3—184.0909 m/z 31 s RT) forms.
Then, we identiﬁed an unexpected metabolite of caffeine with
213.0981 m/z (Fig. 4a, unlabeled, 31 s RT) with the formation of
the isotopically labeled forms (13C3—216.1080 m/z (Fig. 4b),
D3—216.1170 m/z (Fig. 4c)) at the same retention time. The
metabolite 213.0981 m/z corresponds to an elemental composition C8H12N4O3, which corresponds to the addition of two
hydrogens and one oxygen atom. MS2 analysis of 213.0981 m/z
(Fig. 4d), 216.1080 m/z (Fig. 4e), and 216.1170 m/z (Fig. 4f) were
consistent with oxidation (+O) and reduction (+2H) or hydration (+H2O) of the caffeine imidazole. A proposed structure for
this unreported caffeine metabolite is provided (Fig. 4g–i). This
metabolite was detected in mice treated with caffeine (Supplementary Fig. 2a) and also correlated with caffeine in humans
(Supplementary Fig. 2b).
Identiﬁcation of documented xenobiotic exposures. Analysis of
S9 reaction extracts provides authentic xenobiotic metabolites for
generation of MS1, MS2, and retention times, which can support
the identiﬁcation of xenobiotic metabolites in human and mouse
samples. Two of the criteria required for metabolite identiﬁcation
in human and mouse samples can be satisﬁed by the use of m/z
(±3 ppm) and retention time windows (±5 s) for matching
compounds detected in study samples. If MS2 cannot be collected
for the study samples due to low abundance, the third criterion
for identiﬁcation can be satisﬁed if expected ions at their characteristic retention times are detected only in animal or human
samples with documented exposure. For example, in mice treated
4

with bupropion, bupropion (Fig. 5a), hydroxybupropion
(Fig. 5b), and hydrobupropion (Fig. 5c) are detected at the same
accurate mass m/z and retention time as S9-generated
metabolites.
To test this concept in human samples, we used plasma
samples collected from patients with well-documented pharmaceutical use (electronic medical records) receiving care at Emory
University Hospital. HRMS analysis shows that in samples
collected from the one individual who was taking bupropion,
bupropion (Fig. 5d), hydroxybupropion (Fig. 5e), and hydrobupropion (Fig. 5f) were detected at the same accurate mass m/z
and retention time as S9-generated metabolites. Furthermore, we
observed that hydroxybupropion, and hydrobupropion were only
detected in the samples where bupropion was also detected
(Fig. 5g). Acetaminophen, carvedilol, warfarin, and metoprolol
were other medications that were used by individuals in this
cohort. To evaluate whether the expected metabolites of these
medications were correlated with the initial parent compound, we
used xMWAS software, a tool for multi-parameter metabolomewide association analyses. Then, we applied a mass difference
ﬁlter (m/zfeature − m/zparent) on correlated metabolites to generate
reaction-based networks. Partial least squares regression analysis
(r > 0.4) revealed ﬁve distinct clusters, each centered around a
single parent compound. Each parent compound (bupropion
Fig. 5a, acetaminophen Fig. 5i, metoprolol Fig. 5j, carvedilol
Fig. 5k, warfarin Fig. 5l) was correlated with at least one expected
biotransformation product and their associated source fragments,
adducts, and isotopes (Supplementary Fig. 3). These metabolites
were all detected at the same accurate mass m/z and retention
times as those produced from S9 reactions. Thus, the use of
enzyme-generated xenobiotic metabolites as authentic metabolites together with the use of co-detection of related metabolites
provides a strategy for pathway-level identiﬁcation of xenobiotics
and xenobiotic metabolites.
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Identiﬁcation of undocumented xenobiotic exposures. To test
whether the use of accurate mass m/z, RT, and co-detection of
related xenobiotics could be used for identiﬁcation of xenobiotics
in human samples with undocumented environmental, drug, or
dietary exposures, we examined a healthy cohort (n = 120) with

no documented xenobiotic exposures where paired urine and
plasma samples were available. Nicotine, a common environmental xenobiotic that humans can be exposed to through
tobacco products and secondhand smoke, was detected alongside
related metabolites (cotinine, hydroxycotinine, and nicotine
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glucuronide) in 7 out of 120 people in both urine and plasma
(Fig. 6a). Naphthalene, an industrial chemical that can also be
found in mothballs, tobacco smoke, and other environmental
sources, was detected as hydroxynaphthalene sulfate (naphthol
sulfate) and hydroxynaphthalene glucuronide (naphthol glucuronide) in 4 out of 120 people in urine. In two out of the four
individuals with naphthalene exposures detectable in urine,
hydroxynapthalene sulfate was also detected in plasma (Fig. 6a).
Omeprazole, an over-the-counter medication used for the treatment of heartburn, was detected alongside related metabolites
(deoxyomeprazole, omeprazole sulfate, omeprazole glucuronide)
in 7 out of 120 people in urine or plasma. Piperine, a chemical
found in black pepper, was detected in all plasma samples.
Hydroxypiperine and piperine dihydrodiol were correlated with
piperine in plasma (Supplementary Fig. 4). In addition to correlations of related metabolites within a single bioﬂuid, some
compounds were correlated across plasma and urine samples
(Supplementary Fig. 4). All of these chemicals were detected at
the same accurate mass m/z and retention time as S9-enzyme
generated metabolites. While obtaining MS2 spectra for each
metabolite was not possible due to low abundance, at least one
metabolite from each group of related xenobiotics had MS2
spectra that matched MS2 spectra from S9-enzyme generated
metabolites (Fig. 6b). Thus, large-scale HRMS characterization of
S9-enzymatic generated biotransformation products of diverse
xenobiotics provides a strategy to identify exposures based on cooccurrence of related metabolites to complement traditional
approaches to MS-based metabolites identiﬁcation.
Discussion
The purpose of this study was to develop strategies to aid the
identiﬁcation of low abundance xenobiotic metabolites detected
by HRMS. These features, which comprise a majority of detected
features, are not easily identiﬁed using only mass spectrometry6

based criteria which require matching MS1, MS2, and/or MSn
spectra and retention times of unknown metabolites with those
obtained from analysis of authentic standards6,7. Conﬁdence in
metabolite identiﬁcation increases when multiple lines of evidence are provided. For example, while the use of a single
accurate mass MS1 is not sufﬁcient to assign a single elemental
composition23, co-detection of naturally occurring isotopic ions
and adducts increases conﬁdence in assigning elemental compositions to detected ions. Along the same vein, incorporating
biological criteria based on co-detection of related xenobiotic
metabolites increases conﬁdence in the identiﬁcation of xenobiotic exposures in humans. Furthermore, co-detection of related
xenobiotic metabolites in different bioﬂuid types provides additional identiﬁcation conﬁdence for exposure assessment. Since
MS2 and MSn cannot always be collected from low abundance
xenobiotics, generation of xenobiotic pathway metabolites using
enzymatic systems enables co-detection of related xenobiotics and
xenobiotic metabolites (at characteristic m/z and RT) to be used
as criteria for metabolite identiﬁcation. These strategies provide a
complementary approach to increase the conﬁdence of metabolite
identiﬁcations, especially for low abundance xenobiotic
metabolites.
Here, we demonstrate that pooled human liver S9 fraction
preparations in 96-well formats provide a generalized reaction
system suitable for generating Phase I and Phase II metabolites of
several xenobiotics in a single experiment. We demonstrate that
the addition of stable-isotope precursors to metabolite identiﬁcation workﬂows aids structural determinations and identiﬁcation
of unreported metabolites. Furthermore, we show that xenobiotic
metabolites produced from S9 reactions can be considered
authentic metabolites for identiﬁcation. Using ﬁve-minute dual
chromatography HRMS methods aimed at increasing sample
throughput, each 96-well experiment requires one day of duplicate sample analysis and can test eleven compounds with fourtime points. Using this strategy with the assumption that each
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parent xenobiotic reaction generates ﬁve metabolites, ﬁfty-ﬁve
biotransformation products plus eleven parent xenobiotics could
be characterized in a single day of sample analysis. Preliminary
data (Supplementary Fig. 5) shows that 75% of metabolites
characterized from a single chemical incubation can be captured
with pooled incubation strategies. Thus, the adoption of pooled
xenobiotic mixtures into experimental workﬂows could, in principle, increase reaction throughput to more efﬁciently cover
exposome space. As compound libraries are screened with this
approach, it will be necessary to automate data acquisition and
analysis pipelines to enhance data sharing across laboratories.
While pooled human liver S9 fractions are useful models to
predict primary human metabolites in vivo14, other biology-based
systems using puriﬁed enzymes, microsomes, cell lines, primary
human hepatocytes, or other cocultured cell systems24 could also
be used for this application. Future studies could perform a systematic comparison of the performance of our S9 incubations
with cell-based systems and the ability to recapitulate metabolites
detected in human and mouse studies.
Some limitations to this approach require discussion. Not all
xenobiotics undergo appreciable biotransformation from human
enzymes. For these cases, the use of co-detection of related
xenobiotics as a criterion for identiﬁcation cannot be used. Furthermore, heterogeneity in xenobiotic-metabolizing enzyme
expression in populations could cause differences in expression of
Phase I and II metabolites that are co-detected in humans. In
addition, without the use of appropriately labeled stable isotope
precursors (which can be cost-prohibitive for high-throughput
analysis) or use of optimized chromatographic separations (to
increase analyte retention to better separate positional isomers
and identify shifts in analyte polarity resulting from biotransformation), collection of MS2/MSn spectra (which can
identify biotransformation products based on the formation of
common substructures), or additional analytic tools (ion mobility, nuclear magnetic resonance), complete characterization of
stereochemistry or regiochemistry is not yet possible using mass
spectrometry alone. For these cases, metabolites should be identiﬁed with broader nomenclature (e.g., hydroxybupropion versus
(2S,3S)-hydroxybupropion or 4′-hydroxybupropion) without the
use of positional modiﬁcations or stereochemistry, unless additional evidence is provided. Nonetheless, establishing a database
of xenobiotic precursor–product relationships for identiﬁcation of
co-occurring related xenobiotics in samples increases identiﬁcation conﬁdence by providing orthogonal criteria for identiﬁcation
of suspected exposure. Existing criteria for mass spectrometrybased chemical identiﬁcation conﬁdence6,7 do not consider biological criteria as outlined in this article. Therefore, we have
provided mass spectrometry-based criteria alongside orthogonal
biological criteria for compounds identiﬁed in this work. Other
aspects of translation to human analysis could be important, such
as the use of serum versus plasma or the use of different anticoagulants for plasma preparation. These could impact the
detection of speciﬁc chemical classes and could be evaluated in
future studies.
In conclusion, the use of biologically-based enzymatic systems
such as S9 fractions to generate mixtures of authentic xenobiotic
metabolites for the identiﬁcation of xenobiotic pathways provides
a useful strategy for identifying low abundance xenobiotics
detected in human samples. This approach could be adapted to
work with cell-based systems and could be scaled to produce
thousands of xenobiotic metabolites in a single experiment. Used
alongside biological criteria based on co-detection of multiple
veriﬁed xenobiotics within a pathway, adoption of a communitybased xenobiotic identiﬁcation strategy could be developed to
address the current limitations in identifying metabolites of the
tens of thousands of chemicals used in commerce25. Ultimately,

ARTICLE

combining the power of multiplexed enzymatic reactions of
xenobiotics with computational strategies for xenobiotic pathway
enrichment analysis under development for mass spectrometry
data would enable higher conﬁdence identiﬁcation of unknown
xenobiotic exposures.
Methods

Materials. Acetaminophen (APAP) (>99%), β-naphthoﬂavone (β-NF) (>98%),
caffeine (>99%), 13C3-caffeine (>99%), nicotine (>99%), chlorzoxazone (CLZ)
(98%), tolbutamide (>99%), bupropion (98%), warfarin (>98%), carvedilol (>98%),
metoprolol (>98%), adenosine 3′-phosphate 5′-phosphosulfate lithium salt hydrate
(PAPS) (>60%), glutathione (GSH) (98%), acetyl-coenzyme A (acetyl-CoA) (93%),
and HPLC grade acetonitrile were purchased from Sigma-Aldrich (St. Louis, MO).
Caffeine-d3 (1-methyl-d3) (99%) and bupropion-d9 (tert-butyl-d9) (99%) were
purchased from CDN isotopes (Point-Clare, Quebec, Canada). Pazopanib, benzo[a]pyrene, and uridine diphosphate glucuronic acid (UDPGA) (>98%) were
purchased from US Biological (Salem, MA). Other precursors (>95% purity) were
sourced from the Spectrum Collection purchased from Microsource Discovery
Systems (Gaylordsville, CT). Pooled human liver S9 fraction: mixed-gender (from
50 livers, H0640.S9) and NADPH regenerating system (K5000-10) were from
Sekisui Xenotech (Kansas City, KS).
Xenobiotic incubations. Incubations of xenobiotics with human liver S9 fraction
were carried out with minor modiﬁcations to the method of Richardson14. Pooled
human liver S9 fractions (20 mg/ml protein) were aliquoted into 0.5 ml microcentrifuge tubes and, stored at −80 °C, and then thawed at room temperature prior
to use. Stock solutions of 5 mM β-NF, tolbutamide, bupropion, pazopanib, and
benzo[a]pyrene were prepared in DMSO, while 5 mM stock solutions of APAP,
caffeine, nicotine, and chlorzoxazone were prepared in water. Each test compound
stock solution was diluted to 0.3 mM with water prior to incubation with S9
enzymes. The NADPH regenerating system was reconstituted with the addition of
3.5 ml of water to make a ﬁnal volume of 5 ml. Cofactors were combined to form a
4× cofactor stock as follows, prior to addition into the reaction mixture: 10 mM
UDPGA, 2 mM GSH, 2 mg/ml PAPS, 0.1 mM acetyl-CoA, and NADPH regenerating system (1 mM NADP, 5 mM glucose-6-phosphate, 1 unit glucose-6phosphate dehydrogenase). Reactions were carried out at 30 °C on 96-well plates
(Fig. 1). S9 fraction was diluted 10-fold in water immediately before mixing with
0.2 M Tris-Cl, pH 7.5/2 mM MgCl2 and 0.3 mM of the xenobiotic solution in a
1:1:1 ratio (15 μL each). and incubated at 30 °C for 5 min. To start the reaction,
15 μL of 4× cofactor stock was added, and incubation was carried out at 30 °C for
the indicated times. To terminate the reaction, we added a three-fold volume of
acetonitrile, covered the plate with paraﬁlm, vortexed, and froze at −20 °C to
precipitate insoluble materials such as protein. After thawing and centrifugation of
the incubation plate, the supernatants were transferred into polypropylene autosampler vials, which were stored at −20 °C until instrumental analysis.

High-resolution mass spectrometry. Totally, 10 μL aliquots of sample extracts
were analyzed using liquid chromatography (Dionex Ultimate 3000) and Fouriertransform HRMS (Thermo Scientiﬁc Fusion or Thermo Scientiﬁc High-ﬁeld Qexactive). The chromatography system was operated in a dual pump conﬁguration
to enable parallel analyte separation and column ﬂushing. Sample extracts were
injected and analyzed using hydrophilic interaction liquid chromatography
(HILIC) with electrospray ionization (ESI) operated in positive mode and reverse
phase (C18) chromatography with ESI operated in negative mode. For S9 reaction
extracts, each analysis was performed using two biological replicates and a single
technical replicate injection per column. For mouse and human samples, each
analysis was performed using three technical replicate injections per column.
Analyte separation for HILIC was accomplished using a Waters XBridge BEH
Amide XP HILIC column (2.1 mm × 50 mm, 2.5 μm particle size) and eluent
gradient (A = water, B = acetonitrile, C = 2% formic acid) consisting of an initial
1.5 min period of 22.5% A, 75% B, 2.5% C, followed by a linear increase to 75% A,
22.5% B, 2.5% C at 4 min and a ﬁnal hold of 1 min. C18 chromatography was
performed using Higgins Targa C18 2.1 mm × 50 mm, 3 μm particle size) a column
with an eluent gradient (A = water, B = acetonitrile, C = 10 mM ammonium
acetate) consisting of an initial 1 min period of 60% A, 35% B, 5% C, followed by a
linear increase to 0% A, 95% B, 5% C at 3 min and held for the remaining 2 min.
For both methods, mobile phase ﬂow rate was held at 0.35 ml/min for the ﬁrst
1 min, then increased to 0.4 ml/min for the ﬁnal 4 min. The void volume elution
time for each method was 18 s. The high-resolution mass spectrometer collected
data at 120,000 resolution for MS1 data collection. Data were collected from 85 to
1275 m/z for MS1 analysis with additional fragmentation spectra collected for
predicted xenobiotic metabolites of a test substrate using a targeted inclusion list
with data-dependent MS/MS. Quality control samples consisting of pooled xenobiotic reactions were analyzed at the beginning, middle, and end of each analytical
run (every twenty samples) to assess chromatographic peak quality (±8 s) and mass
accuracy (observed mass ±5 ppm of expected mass) for compounds present in the
pool. Additional quality assessment was performed on a compound by compound
basis based upon peak quality and mass accuracy of precursor compounds. This
data is available at the NIH Common Fund’s National Metabolomics Data
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Repository (NMDR) website, the Metabolomics Workbench, http://
www.metabolomicsworkbench.org where it has been assigned project ID
PR001099. The data can be accessed directly via its project https://doi.org/
10.21228/M8N97J.
Processing of mass spectrometry data in S9 experiments. Raw MS1 and MS2
data were processed in xCalibur QualBrowser. Expected metabolites for each
xenobiotic substrate were identiﬁed using literature searches and the web-based
metabolite prediction tool Biotransformer (http://biotransformer.ca)10. Extracted
ion chromatograms were generated from accurate mass MS1 spectra for expected
M + H for HILIC+ or M–H for C18-ions ±3 ppm and plotted using GraphPad
Prism 6.0.
Metabolite identiﬁcation criteria. The present research is focused on improving
capabilities for xenobiotic metabolite identiﬁcation when authentic chemical standards
are not available. These criteria are based on metabolomics standards initiative (MSI)
minimum standards for chemical reporting7. MSI level 1 identiﬁcation requires at least
two orthogonal criteria (accurate mass and retention time or accurate mass/isotope
pattern with MS/MS and retention time) to be matched from an experimental sample
with an authenticated chemical standard analyzed in house. In the present study, at
least three orthogonal criteria were used for metabolite identiﬁcation for enzymatically
generated metabolites and detected xenobiotics in experimental samples as described
below. Authentication of xenobiotics was based on (1) presence of appropriate MS
signals only in samples where xenobiotic was added, (2) accurate mass MS1 ± 3 ppm of
expected masses, and MS2 spectra (if available) matching known or predicted patterns.
Based on MSI criteria, identiﬁcations for precursor xenobiotics were considered level 1
identiﬁcations based on analysis of validated chemical standards. Enzymatically generated xenobiotic metabolites (from S9 reactions) were analyzed as crude extracts and
were not additionally fractionated or puriﬁed prior to sample analysis. Identiﬁcation of
xenobiotic metabolites produced from S9 preparations was based on (1) presence of
predicted xenobiotic metabolite only in samples where xenobiotic was added, (2)
accurate mass MS1 ±3 ppm of expected mass for predicted enzymatic product, and (3)
time-dependent increase in MS1 intensity only in samples where co-substrate for the
enzymatic reaction was added. Based on MSI criteria, identiﬁcations for xenobiotic
metabolites generated enzymatically are considered MSI level 2 (if MS/MS is available)
because spectral data from enzymatically generated metabolites were not compared to
puriﬁed authenticated chemical standards. Identiﬁcation in clinical and experimental
samples was based upon (1) detection of the expected MS1 mass only in the samples
with documented xenobiotic exposure matching the accurate mass MS1 ±3 ppm of
observed mass from authentic xenobiotic, (2) coelution (±5 s) with the authentic
xenobiotic, and (3) co-occurrence of more than one related xenobiotic at characteristic
m/z and retention time as established from analysis of S9 extracts. Mass fragmentation
spectra (MS2) were collected when available and provided a fourth criterion for
identiﬁcation. Satisfying at least three orthogonal criteria as outlined here constituted
level 1 conﬁdence by orthogonal criteria (with two criteria being level 2 conﬁdence,
and only one criterion being level 3 conﬁdence).
Identiﬁcation of unreported metabolites with stable isotopes. Caffeine,
caffeine-d3, 13C3-caffeine, bupropion, and bupropion-d9 were incubated separately
using the S9 fraction conditions described with samples collected at 0 and 24 h.
Following instrumental analysis, data from HILIC/ESI+ analysis were extracted
and aligned using mzMine226. Metabolites increased at 24 h were identiﬁed using a
Pearson’s correlation (R > 0.9 for m/z peak intensity vs. time) for labeled and
unlabeled experiments. A mass difference ﬁlter (based on mass differences between
expected isotope-labeled forms and native forms) was applied to identify metabolites with increases in a corresponding labeled form. Features that did not have a
corresponding increase in a labeled form that co-eluted with the unlabeled form
were considered nonspeciﬁc metabolites.
Mouse samples. All animal procedures were reviewed and approved by the
Institutional Animal Care and Use Committee of Emory University and complied
with all relevant regulations regarding the use of research animals. Female C57BL/
6J mice (aged 6–8 weeks old) from The Jackson Laboratory (Bar Harbor, ME) were
housed under standard conditions and fed a normal diet (LabDiet, St. Louis, MO;
chow 5001) with water ad libitum. Mice were administered a ﬁve-drug cocktail
containing caffeine (5 mg/kg), bupropion (30 mg/kg), tolbutamide (5 mg/kg),
bufuralol (10 mg/kg), and midazolam (3 mg/kg) in saline via oral gavage. Totally,
10 µL of blood was collected from the transected tail tips at 10, 20, 40, 60, 120, 240,
360, 480 min after drug cocktail administration into microcentrifuge tubes containing heparin 10 µL). Samples were prepared with the addition of 95 µL acetonitrile, vortexed, and centrifuged at 12,000g for 5 min. Samples were analyzed as
described above. Mice were monitored for general health, weight loss, and anemia
during drug cocktail treatments to ensure they did not reach IACUC endpoints.
Human samples. Two sample sets were used in this study. Human samples were
obtained with informed consent under IRB00090101 and IRB00007243, which were
approved by the Emory University Institutional Review Board. Both study designs
comply with all relevant regulations regarding the use of human study participants and
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were conducted in accordance to the criteria set by the Declaration of Helsinki. EDTA
plasma samples (n = 51) from nonsmoking individuals with documented pharmaceutical use were from 11 patients participating in a clinical trial at Emory University
Hospital (ClinicaTrials.gov Identiﬁer: NCT02922816, IRB00090101). Of these 11
patients, 6 (55%) were female, 8 (73%) were white, 3 (27%) were Hispanic, and their
median age was 65 years old (IQR 53–73). Repeat samples from each patient were
collected on day 1, day 15, and day 36 of each study visit cycle. During the trial, each
individual continued medications prescribed as part of routine clinical care. Each
individual had a distinct set of medications taken as prescribed. Other demographic
information on these samples was not available. The exposures investigated reﬂect
clinical care decisions for the participants and are not related to the outcomes of the
clinical trial. Urine and EDTA plasma samples from individuals with no documented
pharmaceutical use (n = 120) were from a subset of baseline samples from adults
enrolled in the Emory-Georgia Tech Centers for Health Discovery and Well-Being
(CHDWB) study27–29, which was approved by the Emory University Institutional
Review Board IRB00007243). These individuals were primarily employed by Emory
University or Emory healthcare systems and recruited through the use of ﬂyers posted
around the university or by word of mouth. Participants were required to be 18 years
of age or older with no acute illness or hospitalization within the previous year.
Individuals were excluded by having a current diagnosis of chronic respiratory disease,
chronic infection, pro-inﬂammatory or autoimmune disease, or a current active
malignant neoplasm other than localized basal cancer of the skin. Of these 120 participants, 37 (31%) were male and 87 (69%) were female, and their median age was 53.
Spectral feature tables from these studies were extracted and aligned using
apLCMS30,31 and xMSanalyzer32. Correlation networks of xenobiotics were generated
using xMWAS33 using the PLS regression function with a correlation threshold of 0.4.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Source data for all ﬁgures and supplementary information are provided with this paper.
The raw source data for S9 reactions generated in this study have been deposited in the
Metabolomics Workbench database [https://www.metabolomicsworkbench.org] with
project number PR001099 and https://doi.org/10.21228/M8N97J at the following link:
https://metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID
=ST001715&StudyType=MS&ResultType=5. The processed spectral data and
precursor-product data are available at http://metabolomics.cloud/#/project/CIDC001.
Additional data are available upon reasonable request from the corresponding
authors. Source data are provided with this paper.

Received: 14 September 2020; Accepted: 18 August 2021;

References
1.
2.

Idle, J. R. & Gonzalez, F. J. Metabolomics. Cell Metab. 6, 348–351 (2007).
Uppal, K. et al. Computational metabolomics: a framework for the million
metabolome. Chem. Res. Toxicol. 29, 1956–1975 (2016).
3. Jones, D. P. Sequencing the exposome: a call to action. Toxicol. Rep. 3, 29–45
(2016).
4. Jones, D. P. & Cohn, B. A. A vision for exposome epidemiology: the pregnancy
exposome in relation to breast cancer in the child health and development
studies. Reprod. Toxicol. 92, 4–10 (2020).
5. Rappaport, S. M., Barupal, D. K., Wishart, D., Vineis, P. & Scalbert, A. The
blood exposome and its role in discovering causes of disease. Environ. Health
Perspect. 122, 769–774 (2014).
6. Schymanski, E. L. et al. Identifying small molecules via high resolution mass
spectrometry: communicating conﬁdence. Environ. Sci. Technol. 48,
2097–2098 (2014).
7. Sumner, L. W. et al. Proposed minimum reporting standards for chemical
analysis Chemical Analysis Working Group (CAWG) Metabolomics
Standards Initiative (MSI). Metabolomics 3, 211–221 (2007).
8. Walker, D. I. et al. Deployment-associated exposure surveillance with highresolution metabolomics. J. Occup. Environ. Med. 58, S12–S21 (2016).
9. Walker, D., Go, Y.-M., Liu, K., Pennell, K. & Jones, D. Population screening
for biological and environmental properties of the human metabolic
phenotype. In Metabolic Phenotyping in Personalized and Public Healthcare
(eds Holmes, E., Nicholson, J. K., Darzi, A. W., Lindon, J. C.) 167–211
(Elsevier, 2016).
10. Djoumbou-Feunang, Y. et al. BioTransformer: a comprehensive
computational tool for small molecule metabolism prediction and metabolite
identiﬁcation. J. Cheminform. 11, 2 (2019).
11. Ruttkies, C., Schymanski, E. L., Wolf, S., Hollender, J. & Neumann, S. MetFrag
relaunched: incorporating strategies beyond in silico fragmentation. J.
Cheminform. 8, 3 (2016).

NATURE COMMUNICATIONS | (2021)12:5418 | https://doi.org/10.1038/s41467-021-25698-x | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25698-x

12. Allen, F., Pon, A., Wilson, M., Greiner, R. & Wishart, D. CFM-ID: a web
server for annotation, spectrum prediction and metabolite identiﬁcation from
tandem mass spectra. Nucleic Acids Res. 42, 94–99 (2014).
13. Djoumbou-Feunang, Y. et al. CFM-ID 3.0: signiﬁcantly improved ESI-MS/MS
prediction and compound identiﬁcation. Metabolites 9, 72 (2019).
14. Richardson, S. J., Bai, A., Klkarni, A. A. & Moghaddam, M. F. Efﬁciency in
drug discovery: Liver S9 fraction assay as a screen for metabolic stability. Drug
Metab. Lett. 10, 83–90 (2016).
15. Kolrep, F., Rein, K., Lampen, A. & Hessel-Pras, S. Metabolism of okadaic acid
by NADPH-dependent enzymes present in human or rat liver S9 fractions
results in different toxic effects. Toxicol. Vitr. 42, 161–170 (2017).
16. Li, Y. et al. Current trends in drug metabolism and pharmacokinetics. Acta
Pharm. Sin. B 9, 1113–1144 (2019).
17. Rudolph, W., Remane, D., Wissenbach, D. K. & Peters, F. T. Comparative
study on the metabolism of the ergot alkaloids ergocristine, ergocryptine,
ergotamine, and ergovaline in equine and human S9 fractions and equine liver
preparations. Xenobiotica 49, 1149–1157 (2019).
18. Varkhede, N. R., Jhajra, S., Ahire, D. S. & Singh, S. Metabolite identiﬁcation studies
on amiodarone in in vitro (rat liver microsomes, rat and human liver S9 fractions)
and in vivo (rat feces, urine, plasma) matrices by using liquid chromatography
with high-resolution mass spectrometry and multiple-stage mass spectrometry:
Characterization of the diquinone metabolite supposedly responsible for the drug’s
hepatotoxicity. Rapid Commun. Mass Spectrom. 28, 311–331 (2014).
19. Caspar, A. T., Meyer, M. R., Westphal, F., Weber, A. A. & Maurer, H. H. Nano
liquid chromatography-high-resolution mass spectrometry for the
identiﬁcation of metabolites of the two new psychoactive substances N-(orthomethoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)4-methylmethamphetamine. Talanta 188, 111–123 (2018).
20. Singh, R., Chang, S. Y. & Taylor, L. C. E. In vitro metabolism of a potent HIVprotease inhibitor (141W94) using rat, monkey and human liver S9. Rapid
Commun. Mass Spectrom. 10, 1019–1026 (1996).
21. Chalbot, S. & Morﬁn, R. Human liver S9 fractions: Metabolism of
dehydroepiandrosterone, epiandrosterone, and related 7-hydroxylated
derivatives. Drug Metab. Dispos. 33, 563–569 (2005).
22. Coles, R. & Kharasch, E. D. Stereoselective metabolism of bupropion by
cytochrome P450 2B6 (CYP2B6) and human liver microsomes. Pharm. Res.
25, 1405–1411 (2008).
23. Kind, T. & Fiehn, O. Metabolomic database annotations via query of
elemental compositions: mass accuracy is insufﬁcient even at less than 1 ppm.
BMC Bioinform. 7, 234 (2006).
24. Peisl, B. Y. L., Schymanski, E. L. & Wilmes, P. Dark matter in hostmicrobiome metabolomics: tackling the unknowns—a review. Anal. Chim.
Acta 1037, 13–27 (2018).
25. Liu, K. H. et al. Reference standardization for quantiﬁcation and
harmonization of large-scale metabolomics. Anal. Chem. 92, 8836–8844
(2020).
26. Pluskal, T., Castillo, S., Villar-Briones, A. & Orešič, M. MZmine 2: modular
framework for processing, visualizing, and analyzing mass spectrometry-based
molecular proﬁle data. BMC Bioinform. 11, 395 (2010).
27. Rask, K. J., Brigham Kl Fau - Johns, M. M. E. & Johns, M. M. Integrating
comparative effectiveness research programs into predictive health: a unique
role for academic health centers. Acad. Med. 86, 718–723 (2011).
28. Brigham, K. L. Predictive health: the imminent revolution in health care. J.
Am. Geriatr. Soc. 58, S298–S302 (2010).
29. Tabassum, R. et al. A longitudinal study of health improvement in the Atlanta
CHDWB Wellness Cohort. J. Pers. Med. 4, 489–507 (2014).
30. Yu, T. & Jones, D. P. Improving peak detection in high-resolution LC/MS
metabolomics data using preexisting knowledge and machine learning
approach. Bioinformatics 30, 2941–2948 (2014).

ARTICLE

31. Yu, T., Park, Y., Johnson, J. M. & Jones, D. P. apLCMS–adaptive processing of
high-resolution LC/MS data. Bioinformatics 25, 1930–1936 (2009).
32. Uppal, K. S. et al. xMSanalyzer: automated pipeline for improved feature
detection and downstream analysis of large-scale, non-targeted metabolomics
data. BMC Bioinform. 14, 15 (2013).
33. Uppal, K., Ma, C., Go, Y. M., Jones, D. P. & Wren, J. xMWAS: a data-driven
integration and differential network analysis tool. Bioinformatics 34, 701–702
(2018).

Acknowledgements
This work was supported by U2C-ES030163, P30 ES019776, RC2-DK118619, S10OD018006, UL1-TR002378 Georgia Clinical and Translational Science Alliance (Georgia
CTSA), UM1AI104681, K23AI144036, SSCI Research Scholar Award.

Author contributions
These authors contributed equally: K.H.L. and C.M.L. These authors jointly supervised
the work: E.T.M. and D.P.J. D.P.J. and E.T.M. conceived the study. K.H.L. and C.M.L.
wrote the paper. K.H.L., C.M.L. and G.S. prepared and analyzed samples and performed
data analysis. P.B. and F.C. constructed the supplemental website. K.H.L., C.M.L., G.S.,
M.W., T.R.Z., C.S.K., G.L.M., S.L., E.T.M., Y.M.G. and D.P.J. designed the experiments
and edited the paper. All authors commented on the paper.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41467-021-25698-x.
Correspondence and requests for materials should be addressed to Edward T. Morgan or
Dean P. Jones.
Peer review information Nature Communications thanks Gary Siuzdak and the other
anonymous reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021

NATURE COMMUNICATIONS | (2021)12:5418 | https://doi.org/10.1038/s41467-021-25698-x | www.nature.com/naturecommunications

9

